Smad nuclear interacting protein 1 (SNIP1)

Smad nuclear interacting protein 1 (SNIP1) is a highly conserved nuclear protein comprising 396 amino acids, containing a coiled-coil motif and a C-terminal forkhead-associated (FHA) domain[1][5]. SNIP1 acts as a transcriptional coactivator, enhancing c-Myc-mediated gene expression and inhibiting TGF-β and NF-κB signaling by competing for CBP/p300 transcriptional coactivators[1][3][5]. It also modulates cyclin D1 mRNA stability, is involved in RNA and microRNA biogenesis, and plays important roles in cell cycle progression, apoptosis, inflammation, and tumorigenesis[2][5]. SNIP1 is upregulated in various cancers and has protective roles in cardiac hypertrophy and inflammation[1][2][3]. Mutations in SNIP1 cause neurodevelopmental disorders with seizures, hypotonia, and craniofacial abnormalities[5]. SNIP1 is considered a druggable target for cancer and cardiovascular diseases, with ongoing research into its molecular mechanisms and therapeutic potential[1][3][5].

Other names

SNIP1Smad nuclear-interacting protein 1PML1FHA domain-containing protein SNIP1PML1 homolog (yeast)NEDHCS (Neurodevelopmental Disorder With Hypotonia, Craniofacial Abnormalities, And Seizures)PMRED (Psychomotor retardation, epilepsy, and craniofacial dysmorphism)

For potential drugs: inhibition or modulation of SNIP1 might regulate c-Myc stability, suppress NF-κB or TGF-β-dependent transcription, influence cell cycle arrest, and mitigate pathological hypertrophy or cancer cell proliferation[1][3][5].